The recent flurry of exit activity points to a single thread: after a long stretch of uncertainty, late-stage technology companies and their investors are moving to lock in outcomes rather than wait for ideal conditions. Anthropic is pushing ahead with a listing that falls short of earlier expectations, its founders are taking cash off the table, and Oura has chosen to buy rather than list. The common driver is a preference for certainty over the top of the market.
A Listing That Settles for Less
Anthropic confirmed on Tuesday that its IPO could be one of the biggest ever, even while falling short of previous expectations, according to The Verge. The company's shares are expected to price between $70.00 and $78.00, and the Wall Street Journal's sources indicate Anthropic is aiming for its shares to start trading Thursday or Friday next week.
The wording matters for the Funding & Investment beat. A company can simultaneously claim a landmark listing and concede that it is smaller than hoped. That combination is not a contradiction so much as a statement about the current market: the window is open, but it is not generous. For US technology companies weighing a public listing, Anthropic's decision suggests that an achievable debut is now preferable to an indefinite wait for a better one.
Founders Convert Paper to Cash
TechCrunch reported that all seven Anthropic co-founders will each cash out about $250 million in the IPO, selling exactly the same number of shares at the midpoint of the price range, while leaving the group in control of the company.
The equal sizing is notable. It signals a coordinated decision rather than individual opportunism, and it keeps the founding group's governance position intact even as it diversifies personal exposure. For the investment beat, founder selling in an IPO is usually read as a signal about insider expectations. Here the signal is more nuanced: the founders are not exiting control, but they are converting a portion of their illiquid stakes into cash at a moment when the price range is known and the trading date is near. That is a bet on realized value over hoped-for value, and it is the same instinct driving the broader pattern.
Oura Buys Instead of Listing
Oura's agreement to acquire the AI-native primary care startup Counsel Health for $625 million, as TechCrunch reported, came a few weeks after Oura postponed its up to $2.2 billion IPO indefinitely, citing "uncertainty in the IPO market."
The sequencing is the story. A company that had prepared for a multi-billion-dollar public listing instead deployed capital into an acquisition. That is a reallocation of both money and strategy: rather than raise in public markets and let the market price its prospects, Oura is spending to build the business it would have asked public investors to value. For US technology companies, this is the clearest available evidence that the public and private paths are being weighed against each other in real time, and that the private path is winning for at least some issuers.
